X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Dr. Heath on Recent Approvals in Nonmetastic Prostate Cancer

Dr. Elisabeth Heath, of ZERO – The End of Prostate Cancer’s Medical Advisory Board, discusses the recent recognition of apalutamide (Erleada), enzalutamide (Xtandi), and darolutamide (Nubeqa), for use in the treatment of metastatic prostate cancer.

Watch the video here.

Read the full article from onclive.com

source: OncLive